Lenvatinib
Also known as: Lenvima · Kisplyx
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, lenvatinib is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma that is refractory to radioactive iodine. It is also indicated in the European Union as monotherapy for adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy. Additionally, in the European Union, it is indicated for the treatment of adults with advanced renal cell carcinoma, either in combination with pembrolizumab as first-line treatment, or in combination with everolimus following one prior vascular endothelial growth factor-targeted therapy.
Source: European Medicines Agency (EMA), Lenvima — EPAR, 26/03/2026. © European Medicines Agency. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency. · Source: European Medicines Agency (EMA), Kisplyx — EPAR, 26/03/2026. © European Medicines Agency.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 1603296 lenvatinib
- EMA
- EMEA/H/C/003727, EMEA/H/C/004224
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
EMA (EU) Kisplyx
Kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (RCC): in combination with pembrolizumab, as first-line treatment (see section 5.1). in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
Source: European Medicines Agency (EMA), Kisplyx — EPAR, 26/03/2026. © European Medicines Agency.
Document date: 26/03/2026 · Official document →
EMA (EU) Lenvima
Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
Source: European Medicines Agency (EMA), Lenvima — EPAR, 26/03/2026. © European Medicines Agency.
Document date: 26/03/2026 · Official document →
Related terms in the cited sources
Has an official indication for
- Thyroid cancer Condition
In alphabetical order.
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Lenvatinib approved for in the European Union?
Kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (RCC): in combination with pembrolizumab, as first-line treatment (see section 5.1). in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)-targeted therapy. (Source: European Medicines Agency (EMA), Kisplyx — EPAR, 26/03/2026. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Kisplyx — EPAR, 26/03/2026. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Lenvima — EPAR, 26/03/2026. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.